Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Brunner on the Use of CAR T-cell Therapy to Improve Post-ASCT Responses in Multiple Myeloma

March 20th 2023

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Dr. Brunner on the Utilization of Advanced Imaging Modalities in R/R Multiple Myeloma

March 17th 2023

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

March 15th 2023

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Dr. Richardson on Proteasome Inhibitor/Monoclonal Antibody Combinations in Myeloma

March 14th 2023

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

Unmet Needs and Future Perspectives in Multiple Myeloma Care

March 13th 2023

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

Does Belantamab Have a Place in Multiple Myeloma Treatment?

March 13th 2023

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Preventing Infection in Patients with Multiple Myeloma During Treatment

March 13th 2023

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Dr. Godara on Treatment Strategies Following First Relapse in Multiple Myeloma

March 8th 2023

Amandeep Godara, MBBS, discusses the current treatment strategies following first relapse for patients with multiple myeloma.

Dr. Giralt on the Rationale of the Karmma-3 trial of Ide-cel in R/R Myeloma

March 6th 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

March 6th 2023

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Targets in Multiple Myeloma: FcRH5

March 6th 2023

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma

March 2nd 2023

Dr Jakubowiak discusses interim findings from the ATLAS trial of lenalidomide plus carfilzomib and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.

Effective Utilization of CD38+ Agents, IMiDs Spur Further Clinical Research in Relapsed/Refractory Myeloma

March 2nd 2023

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

Teclistamab Approval Adds to Bucket of Relapsed/Refractory Multiple Myeloma Options

February 28th 2023

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

Dr. Giralt on the Evaluation of Ide-cel in Triple-Class Exposed R/R Myeloma

February 27th 2023

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Targets in Multiple Myeloma: GPRC5D

February 27th 2023

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Data Updates on Immunotherapy Combinations in Multiple Myeloma

February 27th 2023

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma

February 22nd 2023

The FDA has granted a priority review to the biologics license application for elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.

MHRA Approves Selinexor Plus Bortezomib/Dexamethasone for Multiple Myeloma Following 1 Prior Therapy

February 21st 2023

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted full marketing authorization for selinexor in combination with bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

Clinical Activity With High-dose HPN217 Warrants Continued Research in R/R Multiple Myeloma

February 20th 2023

Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.